Skip to main content

Treatment Clinical Trials for Multiple Myeloma/Plasma Cell Myeloma

Review the multiple myeloma/plasma cell myeloma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 197

Testing the Use of Combination Therapy in Adult Patients with Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Status: Active
Location: 595 locations
Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Status: Active
Location: 698 locations
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Status: Active
Location: 511 locations
Iberdomide versus Observation off Therapy after Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Status: Active
Location: 70 locations
Testing the Combination of One Approved Drug and Two Experimental Drugs in Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 39 locations
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Status: Active
Location: 28 locations
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) with the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Status: Active
Location: 27 locations
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 26 locations
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Status: Active
Location: 20 locations
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Status: Active
Location: 16 locations
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Active
Location: 17 locations
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Status: Active
Location: 18 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 16 locations
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Status: Active
Location: 17 locations
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 14 locations
Elotuzumab and Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 14 locations
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Status: Active
Location: 14 locations
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Status: Active
Location: 14 locations
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Status: Active
Location: 11 locations
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Active
Location: 14 locations
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Status: Active
Location: 12 locations
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Status: Active
Location: 10 locations
Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) plus Daratumumab in Newly Diagnosed Multiple Melanoma Patients with Cast Nephropathy or Monoclonal Gammopathy of Renal Significance (MGRS)
Status: Active
Location: 10 locations
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Status: Active
Location: 10 locations
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Active
Location: 10 locations